{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:21:00Z","timestamp":1763018460621,"version":"3.45.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":387,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Janssen Pharmaceutical Companies of Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019720","name":"GlaxoSmithKline Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019720","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jtct.2022.01.026","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T12:19:53Z","timestamp":1643977193000},"page":"258.e1-258.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment"],"prefix":"10.1016","volume":"28","author":[{"given":"Marta","family":"Reinoso-Segura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Caballero-Vel\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4118-7110","authenticated-orcid":false,"given":"Pilar","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Patriarca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Fanin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hareth","family":"Nahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0366-3673","authenticated-orcid":false,"given":"Miquel","family":"Granell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"L\u00f3pez-Corral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan L.","family":"Reguera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Garc\u00eda-Cadenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00f6sta","family":"Gahrton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"P\u00e9rez-Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.01.026_bib0001","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/bjh.14780","article-title":"Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions","volume":"179","author":"Moreau","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.01.026_bib0002","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.2016.71.1663","article-title":"Systematic literature review and network meta-analysis of treatment outcomes in relapsed and\/or refractory multiple myeloma","volume":"35","author":"van Beurden-Tan","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.01.026_bib0003","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.01.026_bib0004","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.bbmt.2014.04.027","article-title":"The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation","volume":"20","author":"Donato","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.01.026_bib0005","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1056\/NEJM199110313251802","article-title":"Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation","volume":"325","author":"Gahrton","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.01.026_bib0006","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.bmt.1703253","article-title":"Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect","volume":"28","author":"Le Blanc","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.01.026_bib0007","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.1995.13.6.1312","article-title":"Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma","volume":"13","author":"Gahrton","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.01.026_bib0008","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1182\/blood.V88.12.4711.bloodjournal88124711","article-title":"Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation","volume":"88","author":"Bj\u00f6rkstrand","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.01.026_bib0009","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.bbmt.2015.09.016","volume":"21","author":"Giralt","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.01.026_bib0010","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","volume":"112","author":"Rosi\u00f1ol","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.01.026_bib0011","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2008-07-170746","article-title":"Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting","volume":"113","author":"Rotta","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.01.026_bib0012","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/sj.leu.2404085","article-title":"Grupo Espa\u00f1ol de Mieloma. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients","volume":"20","author":"P\u00e9rez-Sim\u00f3n","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.01.026_bib0013","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1182\/blood-2006-07-036848","article-title":"Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning","volume":"109","author":"Crawley","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.01.026_bib0014","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.3390\/jcm9113437","article-title":"Allogeneic hematopoietic transplantation for multiple myeloma in the new drugs era: a platform to cure","volume":"9","author":"Mussetti","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtct.2022.01.026_bib0015","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1158\/1078-0432.CCR-03-0781","article-title":"Approval summary for bortezomib for injection in the treatment of multiple myeloma","volume":"10(12 Pt 1)","author":"Bross","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2022.01.026_bib0016","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2567.2007.02761.x","article-title":"Proteasome inhibition suppresses essential immune functions of human CD4+ T cells","volume":"124","author":"Berges","year":"2008","journal-title":"Immunology"},{"key":"10.1016\/j.jtct.2022.01.026_bib0017","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3324\/haematol.2008.005017","article-title":"Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population","volume":"94","author":"Blanco","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.01.026_bib0018","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41409-019-0670-6","article-title":"European Myeloma Network. Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation","volume":"55","author":"Caballero-Vel\u00e1zquez","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.01.026_bib0019","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.01.026_bib0020","doi-asserted-by":"crossref","first-page":"m3176","DOI":"10.1136\/bmj.m3176","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Shah UA","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jtct.2022.01.026_bib0021","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.3390\/cancers13112639","article-title":"CART-cell therapy: recent advances and new evidence in multiple myeloma","volume":"13","author":"Martino","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtct.2022.01.026_bib0022","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","article-title":"European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019","volume":"54","author":"Duarte","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.01.026_bib0023","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1002\/cncr.25228","article-title":"Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up","volume":"116","author":"Shimoni","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.01.026_bib0024","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.01.026_bib0025","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.01.026_bib0026","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0092-8674(94)90482-0","article-title":"The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B","volume":"78","author":"Palombella","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.jtct.2022.01.026_bib0027","first-page":"471","article-title":"Advances in the understanding of mechanisms and therapeutic use of bortezomib","volume":"12","author":"Mujtaba T","year":"2011","journal-title":"Discov Med"},{"key":"10.1016\/j.jtct.2022.01.026_bib0028","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.bbmt.2020.05.015","article-title":"Ixazomib for treatment of refractory chronic graft versus. host disease: a Chronic GVHD Consortium phase II trial","volume":"26","author":"Pidala","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.01.026_bib0029","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.01.026_bib0030","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.01.026_bib0031","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1038\/s41375-020-0813-1","article-title":"Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment","volume":"34","author":"Siegel","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.01.026_bib0032","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.01.026_bib0033","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood.2020006892","article-title":"A randomized phase-2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease","volume":"137","author":"Curtis","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.01.026_bib0034","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.01.026_bib0035","article-title":"Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis","volume":"37","author":"Sun CY","year":"2017","journal-title":"Biosci Rep"},{"key":"10.1016\/j.jtct.2022.01.026_bib0036","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bjh.12410","article-title":"Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients","volume":"162","author":"Caballero-Vel\u00e1zquez","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.01.026_bib0037","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1182\/bloodadvances.2017010686","article-title":"Tandem autologous\/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma","volume":"1","author":"Green","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.01.026_bib0038","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.clml.2019.09.063","article-title":"Profound MRD negativity rates after frontline tandem autologous-allogeneic stem cell transplantation followed by bortezomib maintenance in high-risk or young myeloma patients","volume":"19","author":"LeBlanc","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2022.01.026_bib0039","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2011-04-348292","article-title":"Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 trial","volume":"118","author":"Kneppers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.01.026_bib0040","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.bbmt.2012.11.111","article-title":"Phase I\/II multicenter clinical trial of lenalidomide maintenance after allogeneic hematopoietic cell transplant (alloHCT) in patients with high risk (HR) multiple myeloma (MM)","volume":"19","author":"Becker","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.01.026_bib0041","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.exphem.2012.10.004","article-title":"Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GVHD: results from a phase I\/II dose-finding study","volume":"41","author":"Wolschke","year":"2013","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jtct.2022.01.026_bib0042","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/bmt.2012.142","article-title":"Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory\/relapsed myeloma patients","volume":"48","author":"Kr\u00f6ger","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.01.026_bib0043","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.bbmt.2014.04.014","article-title":"Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation","volume":"20","author":"Alsina","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.01.026_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100792","article-title":"Graft-versus-host disease prophylaxis: pathophysiology-based review on current approaches and future directions","volume":"48","author":"Martinez-Cibrian","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtct.2022.01.026_bib0045","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3324\/haematol.2011.058677","article-title":"The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation","volume":"97","author":"Caballero-Vel\u00e1zquez","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.01.026_bib0046","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1200\/JCO.2012.42.0984","article-title":"Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation","volume":"30","author":"Koreth","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.01.026_bib0047","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3324\/haematol.2017.176859","article-title":"Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results","volume":"103","author":"Koreth","year":"2018","journal-title":"Haematologica"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722000562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722000562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:03:21Z","timestamp":1763003001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722000562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S2666636722000562"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.01.026","relation":{},"ISSN":["2666-6367"],"issn-type":[{"type":"print","value":"2666-6367"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.01.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}